아데노 부속 바이러스 벡터 제조 시장 규모, 점유율, 동향 분석 보고서 : 사업 규모별, 방법별, 치료 분야별, 용도별, 지역별, 부문별 예측(2025-2030년)

Adeno Associated Virus Vector Manufacturing Market Growth & Trends:

The global adeno associated virus vector manufacturing market size is expected to reach USD 2.78 billion by 2030, registering a CAGR of 18.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to the increasing prevalence of chronic diseases like cancers, cystic fibrosis, Duchenne muscular dystrophy, retinitis pigmentosa, and many more. Adeno-associated virus (AAV) vector plays a vital role in the treatment of these diseases. AAV vectors also have a wide range of applications in gene therapy delivery. Companies are engaged in collaborations, mergers, and partnerships for innovative product launches with advancements in R&D.

For instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno's CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.

For instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus's development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.

Adeno Associated Virus Vector Manufacturing Market Report Highlights:

• By the scale of operations, the commercial segment dominated the industry in 2024. Owing to the increasing R&D investment by companies and demand from vaccine manufacturers
• The neurological diseases therapeutic area segment captured the largest share in 2024 due to the high prevalence of chronic neurodegenerative diseases and the effectiveness of the adeno associated virus vector-based therapies to treat these diseases
• Vaccine is considered a key application segment, which held the largest revenue share in 2024 and is likely to remain dominant throughout the forecast period due to the rising demand for vaccine therapeutics and increasing investments & funds for the production of vaccines
• North America has established a strong regional position. The increasing incidence of cancer and high R&D expenditure is encouraging companies in the region to undertake product development, which drives the regional market

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Scale of Operations
  • 1.2.2. Method
  • 1.2.3. Therapeutic Area
  • 1.2.4. Application
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
  • 3.2.1. Market Dynamics
    • 3.2.1.1. Technological advancements in manufacturing vectors
    • 3.2.1.2. Robust pipelines for gene therapies and vaccines
    • 3.2.1.3. Increasing number of emerging players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory, scientific and ethical challenges
    • 3.2.2.2. Production capacity challenges
• 3.3. Business Environment Analysis
  • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.3.2. Porter's Five Forces Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Scale Of Operations Business Analysis

• 4.1. Scale of Operations Segment Dashboard
• 4.2. Global Adeno Associated Virus Vector Manufacturing Market: Scale of Operations Movement Analysis
• 4.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Scale of Operations, 2018 to 2030 (USD Million)
• 4.4. Clinical
  • 4.4.1. Clinical Market, 2018 - 2030 (USD Million)
• 4.5. Preclinical
  • 4.5.1. Preclinical Market, 2018 - 2030 (USD Million)
• 4.6. Commercial
  • 4.6.1. Commercial Market, 2018 - 2030 (USD Million)

Chapter 5. Method Business Analysis

• 5.1. Method Segment Dashboard
• 5.2. Global Adeno Associated Virus Vector Manufacturing Market: Method Movement Analysis
• 5.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
• 5.4. In Vitro
  • 5.4.1. In Vitro Market, 2018 - 2030 (USD Million)
• 5.5. In Vivo
  • 5.5.1. In Vivo Market, 2018 - 2030 (USD Million)

Chapter 6. Therapeutic Area Business Analysis

• 6.1. Therapeutic Area Segment Dashboard
• 6.2. Global Adeno Associated Virus Vector Manufacturing Market: Therapeutic Area Movement Analysis
• 6.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 6.4. Hematological Diseases
  • 6.4.1. Hematological Diseases Market, 2018 - 2030 (USD Million)
• 6.5. Infectious Diseases
  • 6.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
• 6.6. Genetic Disorders
  • 6.6.1. Genetic Disorders Market, 2018 - 2030 (USD Million)
• 6.7. Neurological Disorders
  • 6.7.1. Neurological Disorders Market, 2018 - 2030 (USD Million)
• 6.8. Ophthalmic Disorders
  • 6.8.1. Ophthalmic Disorders Market, 2018 - 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global Adeno Associated Virus Vector Manufacturing Market: Application Movement Analysis
• 7.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Cell Therapy
  • 7.4.1. Cell Therapy Market, 2018 - 2030 (USD Million)
• 7.5. Gene Therapy
  • 7.5.1. Gene Therapy Market, 2018 - 2030 (USD Million)
• 7.6. Vaccine
  • 7.6.1. Vaccine Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. North America Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. U.S. Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Canada Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Mexico Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Germany Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. UK Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. France Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Italy Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Spain Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Denmark Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Sweden Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Norway Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Japan Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. China Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. India Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. South Korea Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Regulatory Framework
    • 8.5.6.5. Australia Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Regulatory Framework
    • 8.5.7.5. Thailand Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Brazil Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Argentina Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Regulatory Framework
    • 8.7.2.5. South Africa Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. Regulatory Framework
    • 8.7.3.5. Saudi Arabia Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Target Disease Prevalence
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Regulatory Framework
    • 8.7.4.5. UAE Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Target Disease Prevalence
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. Regulatory Framework
    • 8.7.5.5. Kuwait Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Participant's Overview
  • 9.4.1. F. Hoffmann-La Roche Ltd
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Charles River Laboratories
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Oxford Biomedica PLC
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. WuXi AppTec
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Yposkesi, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Sarepta Therapeutics, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Pfizer Inc.
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Genezen
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Creative Biogene
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. GenScript (ProBio)
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives